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ABSTRACT 
 
Oral administration is considered as major, convenient route among all other routes of delivery, owing to 
several benefits. But, the poor solubility or enzymatic/metabolic activity are the major concerns in develop-
ing a successful formulation. About 40% of approved drugs which are in the current market and 90% of new 
drug molecules in the developmental pipeline are hydrophobic in nature. The challenge to formulate insol-
uble drugs has met with various approaches to overcome the problems related to solubility, application of 
nanotechnology is one amongst them. The present review deals with various nanocarriers and technologies 
that are proven to be effective in enhancing the bioavilability of poorly soluble drugs. 
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INTRODUCTION 
Oral drug delivery is considered as most suitable, 
common and broadly used as it offers many ad-
vantages in the vein of patient compliance and cost in 
contrast to other routes such as mucosal, transdermal 
and pulmonary [1]. Nevertheless, numerous com-
pounds are ineffective and fails in research and devel-
opment process owing to their low solubility, thus 
minimising the absorption and bioavailability [2-3]. As 
estimated, nearly 40% of approved drugs and 90% of 
molecules in the development stages are suffering 
with the solubility issues. Some of the reasons for this 
are as follows; i) Unavailability of drug in solution 
form, ii) first pass metabolism, iii) inadequate parti-
tion coefficient, iv) degradation of drug in gastro in-
testinal tract and v) p-glycoprotein mediated efflux 
(which can alter the pharmacokinetics) [4]. Quite a 
few approaches have been applied to enhance the 
oral absorption and bioavailability of hydrophobic 
drugs such as, hydrotrophy, micronization and solid 
dispersions. Since few years, nanocarriers are attain 
incredible attention and have shown notable ad-
vantages over conventional systems, especially for 
low soluble drugs [5]. 
Traditional methodologies in enhancing the solu-
bility 
Several conventional methods like Co-solvency and 
surfactant solubilisation; pH modification, micropar-
ticles [6,7] and salt forms; Cyclodextrins (CDs); solid 
state modification including, amorphous forms, solid 
dispersions and co-crystals etc. CDs (Inclusion com-
plexation) are the are the multipurpose excipients 
studied widely for pharmaceutical purposes. Solid 
dispersion is one of the technology that is explored 
broadly in the recent decades specially for the deliv-
ery of low soluble drugs [8]. Localization of conven-
tional dosage forms can also results in enhancing the 
bioavailability as evident from several studies on 
coating [9], mucoadhesion [10,11], and floating ap-
proaches [12]. Fast dissolving tablets and matrix dos-
age forms are also established their application in en-
hancing the absorption [13,14].  
Novel technologies in delivery of poorly soluble 
drugs 
The most frequent nanotechnology based strategies 
used in the formulation development are solid lipid 
nanoparticles, polymeric nanoparticles, dendrimers, 
liposomes, micelles, carobon nanotubes and so forth 
[Figure 1]. which an further provide controlled or 
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sustained or targeted drug delivery. At this time, all 
these novel systems are explored effectively in en-
hancing the therapeutic efficacy especially in anti-
cancer, anti-diabetic and non-steroidal anti-inflam-
matory drugs etc.  
Polymeric nanoparticles are the colloidal carriers 
having particle size in the range of 10-100 nm. Appli-
cation of polymeric nanoparticles can enhance the bi-
oavailability, specificity and reduce toxicity. These 
nanoparticles can be prepared by using several natu-
ral and synthetic polymers [15-19]. These carriers were 
successfully employed for gene delivery and tumor 
targeting. The therapeutic efficacy is significantly de-
pends on biodegradation of polymer and drug re-
lease, usually the drug release follows erosion mech-
anism, diffusion mechanism of combination of both 
[20]. 
Solid Lipid nanoparticles (SLN) are the sub-micron 
colloidal carriers, which were composed of physio-
logical lipids, which are dispersed in aqueous or 
aqueous surfactant solution. SLNs can offer other 
benefits such as non-toxicity, biocompatibility and 
stability, that can be applied for the delivery of hydro-
phobic as well as hydrophillic drugs [21].  
Nanoemulsions are O/W type on emulsions having 
the droplet size of 100-500 nm and can provide ad-
vantages like solubilization of poorly soluble drugs in 
the oil phase and modifies the oil droplet with poly-
mers to prolong the circulation time and also to target 
several tumors passively or actively (by adding lig-
ands) [22]. Commonly used methods are double emul-
sion, low and high energy emulsification etc. SNEDDS 
(Self nano emulsifying drug delivery systems) are an-
hydrous hydrotrophic mixture of surfactant, oil and 
drug, subsequently added to the aqueous phase with 
continuous stirring to form the SNEDDS. Apart from 
the benefits of nanoemulsions, SNEDDS can further 
enhances the chemical, enzymatic stability of drug 
molecule, and ease of scale up and fabrication [23].  
Nanocrystals are having the atoms size in the range 
of 10-400 nm, prepared from nanosuspension con-
sisting of the following steps. i) preparation of nano-
suspension, ii) wet milling, iii) high pressure homog-
enization iv) nanocrystallization and v) spray drying 
[24,25]. Mallesh Kurakula et al., have investigated the ef-
ficacy of nanocrystals in enhancing the solubility and 
dissolution rate of Atorvastatin [26].  
Proliposomes are dry, free flowing powder with a dis-
persed system, which can immediately form a liposo-
mal suspension on contact with water. Owing to their 
solid properties, proliposomes can enhance the phys-
ical stability and promote drug absorption [27-31].  
Dendrimers are the novel innovative polymeric car-
rier having three dimensional structure, narrow pol-
ydispersity index, controlled molecular structure and 
accompanied with several multiple functional 
groups. Dendrimers having the size in between 1 to 
100 nm with three distinct domains i) core, contain-
ing a molecule or atom, ii) repeated branches and iii) 
terminal functional groups. Currently, carbon nano-
tubes are gaining remarkable attention as novel car-
riers owing to their unique features such as a) higher 
cellular uptake, ii) enhanced transmembrane pene-
tration and iii) high drug loading [32]. Apart from all 
these novel systems, nanowires, nanofibers, nanoeth-
anosomes and nanofilms are gained their importance 
in enhancing the oral bioavailability of poorly soluble 
drugs [33-38]. Though the optimizing of several param-
eters in preparing optimum nano-formulation is bit 
complicated, several applications like quality by de-
sign/ response surface methodology or PAT can be 
successfully applied [39-44].  
 
Figure 1: Some of the novel approaches to enhance the solubility and bioavailability of poorly soluble drugs 
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CONCLUSION 
Application of nanotechnology holds a great potential 
in the effective delivery of several poorly soluble 
drugs. All the foresaid technologies are appeared as 
various strategies to revitalize the current develop-
ment process. The colloidal size, low dose size re-
duced toxicity and patient compliance are the main 
benefits, adding a special note to drug targeting. Sev-
eral research works were revealed this. Even though 
the several significant achievements are made in 
nano field, yet there are few challenges that have 
been encountered, like a) scale up, b) variation of 
pharmacokinetics among the individuals and c) cost 
and d) reproducibility. Thus, nanotechnology can of-
fers several opportunities for the researchers to ex-
tend their research and development to overcome the 
foresaid challenges.  
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